About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in San Diego | 12,589 Studies Near You | Clareo Health

Clinical Trials LocationsSan Diego

Clinical Trials in San Diego

Discover 12,589 clinical trials near San Diego, California. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 9401-9420 of 12,589 trials

COMPLETEDPhase 1< 1 mile

Staccato Loxapine Pulmonary Safety in Patients With Asthma

NCT00890175

The purpose of this study is to assess the safety of 2 inhaled doses of Staccato Loxapine within a day in patients with asthma.

Alexza Pharmaceuticals, Inc.52 participantsStarted May 2009

San Diego, California, United States

COMPLETEDPhase 3< 1 mile

Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia

NCT00621504

The purpose of this study is to determine whether ceftaroline is effective and safe in the treatment of Community-Acquired Pneumonia

Bacterial Pneumonia

Forest Laboratories606 participantsStarted Jan 2008

Los Angeles, California, United States • Pasadena, California, United States • Sacramento, California, United States +165 more locations

Find Trials by Condition in San Diego

Breast Cancerin San Diego Lung Cancerin San Diego Prostate Cancerin San Diego Colorectal Cancerin San Diego Melanomain San Diego Leukemiain San Diego Lymphomain San Diego Pancreatic Cancerin San Diego Ovarian Cancerin San Diego Brain Cancerin San Diego

Data from ClinicalTrials.govTerms

COMPLETEDPhase 2< 1 mile

A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia

NCT02279823

In this proof-of-concept study, the safety and efficacy of a solution formulation will be investigated in male subjects with androgenetic alopecia (AGA) after twice daily application for up to 26 weeks.

Androgenetic Alopecia

Intrepid Therapeutics, Inc.95 participantsStarted Oct 2014

San Diego, California, United States • Fridley, Minnesota, United States • Austin, Texas, United States

WITHDRAWNPhase 2/3< 1 mile

Intraoperative Liposomal Bupivacaine Injection in Primary Total Knee Arthroplasty

NCT02341079

The purpose of the study is to evaluate the efficacy of local infiltration of liposomal bupivacaine versus use of an indwelling femoral peripheral nerve block in controlling early postoperative pain in primary total knee arthroplasty. The investigators hope to demonstrate equivalency of treatment modalities to provide an alternative to the commonly used treatment of femoral nerve blockade.

OsteoarthritisOsteoarthritis, KneeArthritis, Degenerative+2 more

United States Naval Medical Center, San DiegoStarted Mar 2015

San Diego, California, United States

COMPLETEDPhase 39.6 miles

The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes

NCT00856986

This trial is conducted in Europe and North America. The aim of this clinical trial is to assess and compare the effect of insulin detemir in combination with liraglutide and metformin versus liraglutide and metformin in subjects with type 2 diabetes. Subjects will continue their own pre-trial metformin treatment during the trial.

DiabetesDiabetes Mellitus, Type 2

Novo Nordisk A/S987 participantsStarted Mar 2009

Alexander City, Alabama, United States • Birmingham, Alabama, United States • Encino, California, United States +230 more locations

No Longer Available11 miles

Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy

NCT02271139

This is an open-label, multicenter, single-arm, expanded access study designed to provide alectinib to participants with ALK-rearranged NSCLC after disease progression on or intolerance to prior ALK tyrosine kinase inhibitor (TKI) therapy. Participants will receive alectinib until disease progression, unacceptable toxicity, withdrawal of consent, patient or physician decision to discontinue treatment, death, alectinib becomes commercially available in the United States following approval of alectinib by the FDA, or the Sponsor decides to close the trial, whichever occurs first (approximately 15 months).

Non-Small Cell Lung Cancer

Genentech, Inc.

Bimingham, Alabama, United States • Daphne, Alabama, United States • Mobile, Alabama, United States +42 more locations

COMPLETEDPhase 319 miles

The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus

NCT00700817

This trial is conducted in Europe and North America. The aim of this trial is to compare the effect on blood sugar control of liraglutide or sitagliptin, both in combination with metformin, in subjects with type 2 diabetes inadequately controlled with metformin alone. The trial has been extended by 52 weeks. The extension will consist of two 26-week periods: 1. Week 27-52 after randomisation \- All subjects will continue receiving sitagliptin or liraglutide at unchanged dose and dosing regimen. 2. Week 53-78 after randomisation * Subjects receiving sitagliptin at the end of week 52 after randomisation will discontinue sitagliptin and will be randomised 1:1 to liraglutide 1.2 mg/day or liraglutide 1.8 mg/day. Liraglutide will be initiated at a dose of 0.6 mg/day, and increased to 1.2 mg/day or 1.8 mg/day in weekly intervals. * Subjects receiving liraglutide 1.2 mg/day or 1.8 mg/day at the end of week 52 after randomisation will continue the treatment at unchanged dose and dosing regimen. Trial completion is planned for June 2010.

DiabetesDiabetes Mellitus, Type 2

Novo Nordisk A/S665 participantsStarted Jun 2008

Birmingham, Alabama, United States • Escondido, California, United States • Fresno, California, United States +163 more locations

COMPLETEDPhase 381 miles

The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

NCT01617434

This trial is conducted in Asia, Europe and North and South America. The aim of the trial is to investigate the effect of liraglutide versus placebo when added to basal insulin analogues with or without metformin in subjects with type 2 diabetes.

DiabetesDiabetes Mellitus, Type 2

Novo Nordisk A/S451 participantsStarted Sep 2012

Phoenix, Arizona, United States • Anaheim, California, United States • Fresno, California, United States +83 more locations

COMPLETEDNA84 miles

Micro-Layer Ablation of Barrett's Metaplasia- A Two-Phase, Multi-Center Trial - Extension of Follow-up to 5 Years

NCT00489268

This study was conducted in 2 serial phases (dosimetry phase and effectiveness phase) to evaluate a balloon-based ablation device (HALO360) that delivers a pre-set amount of energy density (J/cm2) to barrett's tissue. The dosimetry phase evaluated the dose-response and the safety of delivering 6 to 12 J/cm2. The effectiveness phase used 10 J/cm2 delivered twice for all patients, followed by Esophagogastroduodenoscopy (EGD) with biopsies at 1, 3, 6, and 12 months. A second ablation procedure was performed if Barretts esophagus (BE) was present at 1 or 3 months. A complete response (CR) was defined as all biopsy specimens negative for Barrett's Esophagus at 12 months. The effectiveness phase of the present study was extended to a 2.5-year follow-up. This trial incorporated an opportunity for persistent BE to be treated with a focal ablation device (HALO90), achieving a CR in 98.4% of patients by the 2.5-year follow-up,the results of which were published . There is ample evidence that RadioFrequency Ablation (RFA) for Barrett's esophagus is effective and safe. Having additional follow-up (5 years) would add valuable information to the literature, thus aiding the physician in making patient management decisions about the appropriate follow-up interval after RFA.

Barrett Esophagus

Covidien, GI Solutions102 participantsStarted Nov 2003

Scottsdale, Arizona, United States • Orange, California, United States • Boston, Massachusetts, United States +7 more locations

COMPLETEDPhase 489 miles

Open-Label, Safety Study Evaluating the Use of Dexmedetomidine in Pediatric Subjects Undergoing Procedure-Type Sedation

NCT01519167

The objective of this study is to evaluate the safety of dexmedetomidine in a pediatric population requiring non-intubated, spontaneous breathing, moderate to deep sedation (NI-MDS) for elective diagnostic or therapeutic procedures, expected to take more than 30 minutes.

UltrasoundCT ScansMRIs

Hospira, now a wholly owned subsidiary of Pfizer91 participantsStarted Oct 2012

Little Rock, Arkansas, United States • Anaheim, California, United States • Stanford, California, United States +8 more locations

COMPLETEDPhase 393 miles

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

NCT01371734

This is a double-blind study evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) versus placebo in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder (MDD).

Major Depressive Disorder

Pfizer363 participantsStarted Aug 2011

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Tucson, Arizona, United States +39 more locations

COMPLETEDPhase 394 miles

Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects

NCT00840086

This trial is conducted in Asia, Europe, and North and South America. The trial consists of a main trial and a sub-trial. The main trial investigates safety and efficacy of turoctocog alfa (recombinant factor VIII, rFVIII (N8)) in haemophilia A subjects, while the sub-trial investigates safety and efficacy of turoctocog alfa in prevention and treatment of bleeding episodes during surgical procedures.

Congenital Bleeding DisorderHaemophilia A

Novo Nordisk A/S150 participantsStarted Apr 2009

Little Rock, Arkansas, United States • Long Beach, California, United States • Tampa, Florida, United States +60 more locations

COMPLETEDPhase 2109 miles

A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma

NCT00848926

This is a single-arm, open-label, multicenter, pivotal clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory Hodgkin lymphoma.

Disease, Hodgkin

Seagen Inc.102 participantsStarted Feb 2009

Birmingham, Alabama, United States • Duarte, California, United States • Los Angeles, California, United States +24 more locations

COMPLETEDPhase 2111 miles

Pazopanib in Treating Patients With Recurrent Glioblastoma

NCT00459381

This phase II trial is studying the side effects and how well pazopanib works in treating patients with recurrent glioblastoma. Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor

Adult Giant Cell GlioblastomaAdult GlioblastomaAdult Gliosarcoma+1 more

National Cancer Institute (NCI)35 participantsStarted May 2007

Los Angeles, California, United States • San Francisco, California, United States • Bethesda, Maryland, United States +6 more locations

COMPLETEDPhase 2/3111 miles

Vitamin D/Calcium Polyp Prevention Study

NCT00153816

Extensive experimental and observational data suggest that intake of calcium and of vitamin D exert protective effects on colorectal neoplasia. Building on their previous work, the investigators will investigate the chemopreventive effect of vitamin D in the large bowel, to study whether calcium with vitamin D is more effective than calcium alone, and to confirm their positive finding regarding calcium. The goal of this study is the development of chemopreventive combinations that will reduce risk of colorectal neoplasia sufficiently to permit the lengthening of surveillance intervals in most patients and to clarify important issues regarding the mechanisms of colorectal carcinogenesis and chemoprevention.

Colorectal CancerPolypsAdenomas

Dartmouth-Hitchcock Medical Center2,813 participantsStarted Jul 2004

Los Angeles, California, United States • Denver, Colorado, United States • Atlanta, Georgia, United States +8 more locations

COMPLETEDNA111 miles

SuperNOVA Clinical Stenting Trial

NCT01292928

The primary objective of this clinical study is to determine whether the Innova Stent System shows acceptable performance in long-term (12-month) safety rates and vessel patency when treating femoropopliteal lesions.

Atherosclerosis of Native Arteries of the Extremities, Unspecified

Boston Scientific Corporation299 participantsStarted Apr 2011

Birminham, Alabama, United States • Los Angeles, California, United States • Atlanta, Georgia, United States +46 more locations

COMPLETEDPhase 2/3299 miles

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

NCT01572727

This study evaluated whether the addition of daily BKM120 to weekly paclitaxel was effective and safe in treating patients with HER2- locally advanced or metastatic breast cancer.

Novartis Pharmaceuticals416 participantsStarted Aug 2012

Chandler, Arizona, United States • Phoenix, Arizona, United States • Fayetteville, Arkansas, United States +109 more locations

COMPLETEDPhase 3365 miles

Individualized Therapy For Asthma in Toddlers

NCT01606306

The INFANT study will test whether, in preschool children 12-59 months of age with persistent asthma, the following Step 2 asthma therapies will provide similar degrees of asthma control: 1. Daily inhaled corticosteroid (ICS) treatment, 2. Daily leukotriene receptor antagonist (LTRA) treatment, and 3. As-needed ICS plus short-acting beta agonist (as-needed ICS/SABA) rescue treatment.

Milton S. Hershey Medical Center300 participantsStarted Feb 2013

Tucson, Arizona, United States • Oakland, California, United States • San Francisco, California, United States +10 more locations

WITHDRAWNPhase 2431 miles

PRO 140 for Human Immunodeficiency Virus Infection

NCT02257788

PRO 140 2103 is a multicenter, randomized parallel group study, conducted in male and female adult subjects infected with CCR5-tropic HIV-1.

Drexel UniversityStarted Sep 2014

Stanford, California, United States • Denver, Colorado, United States • St Louis, Missouri, United States +4 more locations

COMPLETEDNA631 miles

Stepped Enhancement of PTSD Services Using Primary Care (STEPS UP): A Randomized Effectiveness Trial

NCT01492348

The overall objective of this study is to test the effectiveness of a systems-level approach to primary care recognition and management of PTSD and depression in the military health system. More specifically, the investigators will test the effectiveness of a telephone care management with preference-based stepped PTSD/depression care--STepped Enhancement of PTSD Services Using Primary Care (STEPS UP)--as compared to Optimized Usual Care (OUC). Primary Hypothesis 1: Active duty primary care patients with PTSD, depression, or both who are randomly assigned to STEPS UP will report significantly greater reductions in PTSD and depression symptom severity compared to participants assigned to OUC over 12-months of follow-up. Hypothesis 2: Active duty primary care patients with either PTSD, depression, or both who are randomly assigned to STEPS UP will report significantly greater improvements in somatic symptom severity, alcohol use, mental health functioning, and work functioning compared to participants assigned to OUC over 12-months of follow-up. Hypothesis 3: The STEPS UP program will be both more costly and more effective compared to OUC over the 12-months of follow-up, and will have a favorable cost-effectiveness ratio in terms of dollars per quality adjusted life years saved. Hypothesis 4: Active duty primary care patients participating in STEPS UP, their clinicians, care managers, and family members will report that STEPS UP is acceptable, effective, satisfying, and appropriate PTSD and depression care.

Posttraumatic Stress Disorder (PTSD)Depression

Henry M. Jackson Foundation for the Advancement of Military Medicine666 participantsStarted Jan 2012

Fort Carson, Colorado, United States • Fort Stewart, Georgia, United States • Fort Campbell, Kentucky, United States +3 more locations

PreviousPage 471 of 630Next

Diabetes

in San Diego

Heart Diseasein San Diego